Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

Ghinnagow R, De Meester J, Cruz LJ, Aspord C, Corgnac S, Macho-Fernandez E, Soulard D, Fontaine J, Chaperot L, Charles J, Soncin F, Mami-Chouaib F, Plumas J, Faveeuw C, Trottein F.

Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017.

2.

Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Ghinnagow R, Cruz LJ, Macho-Fernandez E, Faveeuw C, Trottein F.

Front Immunol. 2017 Jul 27;8:879. doi: 10.3389/fimmu.2017.00879. eCollection 2017. Review.

3.

Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.

Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C.

J Immunol. 2014 Jul 15;193(2):961-9. doi: 10.4049/jimmunol.1303029. Epub 2014 Jun 9.

Supplemental Content

Loading ...
Support Center